Advanced

After 6 years with Xolair; a 3-year withdrawal follow-up

Nopp, A.; Johansson, S. G. O.; Adedoyin, J.; Ankerst, Jaro LU ; Palmqvist, M. and Oman, H. (2010) In Allergy 65(1). p.56-60
Abstract
P>Background: This study reports the clinical and immunological state of patients 3 years after a 6-year period of Xolair treatment for severe allergic asthma. Methods: The patient's cat allergen sensitivity, measured as CD-sens, IgE and IgE- and IgG4 antibodies, was analysed and compared with asthma severity evaluated from FEV1 and a questionnaire. Results: Three years after treatment with Xolair was stopped, 12/18 patients reported improved or unchanged asthma compared with ongoing Xolair treatment. Most of the patients were in a stable clinical condition, 16/18 had not increased nightly asthma attacks and 14/18 little or no increase in medication. The CD-sens to cat was still significantly lower (P < 0.02) than untreated patients... (More)
P>Background: This study reports the clinical and immunological state of patients 3 years after a 6-year period of Xolair treatment for severe allergic asthma. Methods: The patient's cat allergen sensitivity, measured as CD-sens, IgE and IgE- and IgG4 antibodies, was analysed and compared with asthma severity evaluated from FEV1 and a questionnaire. Results: Three years after treatment with Xolair was stopped, 12/18 patients reported improved or unchanged asthma compared with ongoing Xolair treatment. Most of the patients were in a stable clinical condition, 16/18 had not increased nightly asthma attacks and 14/18 little or no increase in medication. The CD-sens to cat was still significantly lower (P < 0.02) than untreated patients with allergic asthma and lower than expected from their serum IgE antibody levels. Conclusion: Most of the patients in this study had, still 3 years after closing of 6 years Xolair treatment, a surprisingly mild and stable asthma. Interestingly, the observed, considerable, downregulation of basophil allergen sensitivity, CD-sens, most likely representing mast cell allergen sensitivity, contributed to the clinical results. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
omalizumab, CD-sens, IgE antibody
in
Allergy
volume
65
issue
1
pages
56 - 60
publisher
Wiley-Blackwell
external identifiers
  • wos:000272630200008
  • scopus:72049131312
ISSN
1398-9995
DOI
10.1111/j.1398-9995.2009.02144.x
language
English
LU publication?
yes
id
21d15b7f-66e9-4a76-a1df-283fd62b27ac (old id 1535590)
date added to LUP
2010-01-25 15:50:01
date last changed
2018-05-29 11:40:05
@article{21d15b7f-66e9-4a76-a1df-283fd62b27ac,
  abstract     = {P&gt;Background: This study reports the clinical and immunological state of patients 3 years after a 6-year period of Xolair treatment for severe allergic asthma. Methods: The patient's cat allergen sensitivity, measured as CD-sens, IgE and IgE- and IgG4 antibodies, was analysed and compared with asthma severity evaluated from FEV1 and a questionnaire. Results: Three years after treatment with Xolair was stopped, 12/18 patients reported improved or unchanged asthma compared with ongoing Xolair treatment. Most of the patients were in a stable clinical condition, 16/18 had not increased nightly asthma attacks and 14/18 little or no increase in medication. The CD-sens to cat was still significantly lower (P &lt; 0.02) than untreated patients with allergic asthma and lower than expected from their serum IgE antibody levels. Conclusion: Most of the patients in this study had, still 3 years after closing of 6 years Xolair treatment, a surprisingly mild and stable asthma. Interestingly, the observed, considerable, downregulation of basophil allergen sensitivity, CD-sens, most likely representing mast cell allergen sensitivity, contributed to the clinical results.},
  author       = {Nopp, A. and Johansson, S. G. O. and Adedoyin, J. and Ankerst, Jaro and Palmqvist, M. and Oman, H.},
  issn         = {1398-9995},
  keyword      = {omalizumab,CD-sens,IgE antibody},
  language     = {eng},
  number       = {1},
  pages        = {56--60},
  publisher    = {Wiley-Blackwell},
  series       = {Allergy},
  title        = {After 6 years with Xolair; a 3-year withdrawal follow-up},
  url          = {http://dx.doi.org/10.1111/j.1398-9995.2009.02144.x},
  volume       = {65},
  year         = {2010},
}